SGLT2 Inhibitors Treatment Market size was valued at USD 6.42 billion in 2024 and is set to exceed USD 21.14 billion by 2037, registering over 9.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of SGLT2 inhibitors treatment is evaluated at USD 7.44 billion.
The increasing prevalence of diabetes has fuelled the demand for innovative products, advanced technologies, and personalized solutions. According to the International Diabetes Federation, nearly 783 million adults will be living with diabetes by the end of 2045.
Government efforts to raise awareness of the disease to help in cure and diagnosis at an earlier stage are anticipated to elevate the market’s growth. Moreover, this is leading to growing awareness among people related to diabetes mellitus, and it’s treatment methods.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.6% |
|
Base Year Market Size (2024) |
USD 6.42 billion |
|
Forecast Year Market Size (2037) |
USD 21.14 billion |
|
Regional Scope |
|
Application (Glucose Dissipation, Blood Transfusion)
The glucose dissipation segment is estimated to hold 56% share of the global SGLT2 inhibitors treatment market during the forecasted timeframe. Due to the advancement in glucose dissipation, the SGLT2 treatment market is addressed the unbeatable growth of 8.6% over the years. In order to decrease high blood glucose, the SGLT2 inhibitors work by a new mechanism to reduce renal tubular glucose reabsorption and thus decrease blood glucose levels without inducing the release of insulin.
End Users (Hospitals, Clinics, Diagnostic Centers)
SGLT2 inhibitors treatment market from the diagnostic centers sector is predicted to show the largest share of 42 % by the end of 2037. The qualified healthcare professionals in diagnostic centers with a growing estimation of 14% per annum, such as endocrinologists or primary care physicians, often diagnose and prescribe SGLT2 inhibitors after thoroughly evaluating a patient's medical history, present health, and needs for diabetic management. Moreover, the rising investment in diagnostic services is further expected to boost the segment’s growth. For instance the National Health Service, spends more than USD 6 billion on more than 90 diagnostic services in a year.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
|
End User |
|
North America Market Analysis
North America industry is predicted to account for largest revenue share of 32% by 2037. With the increasing prevalence of obesity and lifestyle changes in the region, chronic diseases are growing on a yearly basis. Approximately 50 % of Americans suffer from at least one chronic disease every year. Additionally, it is predicted that the region's high healthcare spending will spur market expansion. According to data from the World Bank, the area of North America spent 16.415% of its total GDP on healthcare.
Asia Pacific Market Analysis
Asia Pacific region is expected to witness the fastest growth of 8.35% during the forecast period. The factors such as rising disposable income, increasing social organization awareness, improving health care facilities, and more R&D activities are expected to drive the growth of the market in the Asia-pacific region.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?